Trial Profile
RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ILV-094 ADMINISTERED SUBCUTANEOUSLY TO SUBJECT WITH RHEUMATOID ARTHRITIS.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2022
Price :
$35
*
At a glance
- Drugs Fezakinumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Wyeth Pharmaceuticals
- 11 Apr 2011 Planned end date changed from 1 Feb 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 12 Oct 2010 Planned end date changed from Dec 2010 to Feb 2011 as reported by ClinicalTrials.gov.
- 09 Jan 2010 Additional locations identified as reported by ClinicalTrials.gov.